GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vigil Neuroscience Inc (NAS:VIGL) » Definitions » Shares Outstanding (Basic Average)

VIGL (Vigil Neuroscience) Shares Outstanding (Basic Average) : 40.58 Mil (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Vigil Neuroscience Shares Outstanding (Basic Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Vigil Neuroscience's average basic shares outstanding for the quarter that ended in Sep. 2024 was 40.58 Mil.


Vigil Neuroscience Shares Outstanding (Basic Average) Historical Data

The historical data trend for Vigil Neuroscience's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vigil Neuroscience Shares Outstanding (Basic Average) Chart

Vigil Neuroscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Shares Outstanding (Basic Average)
- 28.26 31.69 38.71

Vigil Neuroscience Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.81 38.83 39.86 40.57 40.58

Vigil Neuroscience Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Vigil Neuroscience  (NAS:VIGL) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Vigil Neuroscience Shares Outstanding (Basic Average) Related Terms

Thank you for viewing the detailed overview of Vigil Neuroscience's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Vigil Neuroscience Business Description

Industry
Traded in Other Exchanges
N/A
Address
100 Forge Road, Suite 700, Watertown, MA, USA, 02472
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
Executives
Ivana Magovcevic-liebisch director, officer: President and CEO 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Christopher Silber officer: Chief Medical Officer C/O VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472
Budd Haeberlein Samantha L. director VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472
Gray David L. F. officer: Chief Science Officer VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472
Spyridon Papapetropoulos officer: Chief Medical Officer C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE CA 94608
Suzanne Louise Bruhn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Clay Thorp director C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Evan Thackaberry officer: SVP, Head of Early Development VIGIL NEUROSCIENCE, INC., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Jennifer Lynn Ziolkowski officer: Chief Financial Officer C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Christopher Verni officer: General Counsel VIGIL NEUROSCIENCE, INC., 1 BROADWAY, 7TH FLOOR, SUITE 07-300, CAMBRIDGE MA 02142
Mary Thistle director C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Vida Ventures Gp Iii, L.l.c. 10 percent owner 455 MARKET STREET, SUITE 1420, SAN FRANCISCO CA 94105
Northpond Ventures Gp, Llc 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Stefan Vitorovic director C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Bruce Booth director 890 WINTER STREET, SUITE 320, WALTHAM MA 02451